我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

黄芪多糖联合放疗对小鼠H22肝癌移植瘤的放射增敏及免疫功能的影响*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2017年06期
页码:
9-13
栏目:
实验研究
出版日期:
2018-03-19

文章信息/Info

Title:
Effect of Astragalus Polysaccharide Combined with Radiotherapy on Radiosensitivityand Immune Function of Transplanted Tumor in Mice
作者:
吕心明徐金芬闫呈新△薛递新孙瑶瑶
泰山医学院附属莱钢医院,山东 莱芜 271126
Author(s):
LYU Xinming XU Jinfen YAN Chengxin XUE Dixin SUN Yaoyao
Lai-Gang Hospital Affiliated to Taishan Medical College, Laiwu 271126, China
关键词:
黄芪多糖 放射增敏 肝癌 免疫功能小鼠
Keywords:
astragalus polysaccharide radiosensitivity hepatocellular carcinoma immunological function mouse
分类号:
R735.7
DOI:
10.19288/j.cnki.issn.1000-2723.2017.06.003
文献标识码:
A
摘要:
目的 探讨黄芪多糖联合放疗对小鼠H22肝癌皮下移植瘤的放射增敏作用及免疫功能的影响。方法 建立小鼠H22移植瘤模型,将50只小鼠分为A组(对照组)、B组(化疗组)、C组(低剂量黄芪多糖联合化疗组)、D组(中剂量联合化疗组)、E组(高剂量联合化疗组),观察各组小鼠肿瘤生长情况及免疫功能变化。结果 随着联合黄芪多糖药物浓度的增加,肿瘤3倍倍增时间(TGT3)、肿瘤生长延迟时间(TGD)以及增敏系数(EF)值均有所增加;治疗14d,各治疗组小鼠瘤体重量均显著低于A组,且E组小鼠瘤体重量明显低于其他各组(P<0.05),随着黄芪多糖药物浓度的增加,抑瘤率越高;各治疗组小鼠平均生存期均显著长于A组(P<0.05),且随着联合运用黄芪多糖药物浓度的增加,小鼠平均生存期和生命延长率显著增加(P<0.05);各治疗组小鼠免疫功能各指标均较A组显著降低(P<0.05)。结论 黄芪多糖联合放疗有增敏作用,能够抑制肿瘤生长,延长移植瘤小鼠生存期,提高小鼠的免疫功能,有一定的剂量依赖。
Abstract:
Objective To explore the effects of astragalus polysaccharide combined with radiotherapy on radiosensitization of H22 transplanted hepatocarcinoma and immunologic function in mice. Methods Establishment of mouse H22 transplanted tumor model, 50 mice were divided into A group(control group), B group(chemotherapy group), group C(low dose of Astragalus Polysaccharides combined with chemotherapy group), group D(middle dose chemotherapy group), E group(Gao Jiliang chemotherapy group), the growth situation and change observation on the immune function of tumor mice. Results With the increase of drug concentration combined with astragalus polysaccharide, TGT3, TGD and EF values were increased; treatment of 14d, the tumor weight of mice in treatment group were lower than A group and E group, and lower than the other groups, with the increase of drug concentration of Astragalus, the inhibition rate is higher; the average survival period of all treatment groups were longer than that of group A, and with the increase of drug combined with astragalus; the index of immune function in mice in each treatment group were lower than those in A group, and the combined use of Astragalus polysaccharide. Conclusion Astragalus polysaccharide combined with radiotherapy has radiosensitizing effect, can inhibit tumor growth, prolong the survival time of mice with transplanted tumor and increase the immunological function of mice.

参考文献/References

[1] 龚敏,任庆兰. β-榄香烯对小鼠乳腺癌移植瘤放疗的增敏效果及对血管形成的影响[J]. 中国临床药理学杂志,2015,23(18):1859-1862.
[2] Borena W,Strohmaier S,Lukanova A,et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults[J]. Int J Cancer,2012,131(1):193-200.
[3] 刘伟,徐鑫,王英芳,等. 光敏剂喜泊分对H22肝癌小鼠移植瘤的放射增敏效果[J]. 中国老年学杂志,2016,36(23):5841-5844.
[4] Law AL,Ng WT,Lee MC,et al. Treatment of primary liver cancer using highly-conformalradiotherapy with kV-image guidance and respiratory control[J]. Radiother Oncol,2012,102(1):56-61.
[5] Jung SH,Yoon SM,Park SH,et al. Four-dimensional dose evaluation using deformable image registration in radiotherapy for liver cancer[J]. Med phys,2013,40(1):011706.
[6] 王维,段碧霞,曾丽. PARP抑制剂对Lewis肺癌细胞及移植瘤放疗增敏作用及其机制[J]. 中国肺癌杂志,2016,19(1):16-23.
[7] Guo L,Bai SP,Zhao L,et al. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer:effects on quality of life and survival[J]. Med Oncol,2012,29(3):1656-1662.
[8] Zhao M,Zhang ZF,Ding Y,et al. Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-κB in C2C12 myotubes[J]. Molecules,2012,17(6):7083-7092.
[9] 刘淑珍,张卿. 选择性COX-2抑制剂尼美舒利对肺癌放射治疗增敏作用及其机制研究[J]. 国际呼吸杂志,2016,36(11):823-828.
[10] Zan R,Selivan G,Christen CL,et al. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53[J]. Clin Cancer Res,2011,17(9):2830-2841.
[11] Jambo KC,Banda DH,Kankwatira AM,et al. Small alveolar macrophagesare infected preferentially by HIV and exhibit impaired phagocytic function[J]. Mucosal Immunol,2014,7(5):1116-1126.
[12] Fossat L,Ling GS,Cortini A,et al. Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells[J]. PLoS One,2013,8(2):e57082.
[13] 林秀欣,李春鸣,饶建,等. 顺铂与紫杉醇同期联合放疗治疗局部晚期鼻咽癌临床疗效比较[J]. 海南医学,2016,27(16):2693-2695.
[14] Kunz M,Thon N,Eigenbrod S,et al. Hot spots in dynamic(18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas[J]. Neuro Oncol,2011,13(3):307-316.
[15] 王正安,刘燕青,黄飞,等. 不同增敏药物联合放疗治疗恶性肿瘤的临床效果分析[J]. 肿瘤药学,2017(3):364-369.
[16] 向元俤,刘卫红,吴娟,等. 汉黄芩苷对鼻咽癌裸鼠移植瘤模型的放疗增敏作用及其机制研究[J]. 中国耳鼻咽喉颅底外科杂志,2016,22(5):383-387.
[17] 和劲光. 增敏药剂联合放疗在肿瘤治疗中的效果分析[J]. 中外医学研究,2016,14(12):57-58.
[18] 蔡亮,李光. 埃克替尼联合放疗对鼻咽高分化鳞癌细胞系的增敏效应[J]. 中国新药与临床杂志,2015,32(8):626-629.
[19] Li Z,Tuteja G,Schug J,et al. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer[J]. Cell,2012,148(1):72-83.
[20] 唐心宇,曹远东,孙新臣. CXCL12受体抑制剂调控三阴性乳腺癌放射治疗的敏感性[J]. 临床肿瘤学杂志,2017,23(11)973-977.

备注/Memo

备注/Memo:
* 基金项目: 山东省保健科技协会课题(2016BJ0014)
收稿日期: 2017 - 11- 13
作者简介: 吕心明(1972-),男,山东莱芜人,主管技师,研究方向:肿瘤放疗的研究。
△通信作者: 闫呈新,E-mail:petct001@163.com
更新日期/Last Update: 2017-12-20